Regeneron Pharmaceuticals, Inc. — FY 2020 Form 10-K Summary
Business context and reporting period
Regeneron is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases. The filing covers the fiscal year ended December 31, 2020, including fourth-quarter results. The company operates as one business segment.
Key commercial products include EYLEA, Dupixent, Libtayo, Praluent, Kevzara, Inmazeb, ARCALYST, and ZALTRAP. REGEN-COV received FDA Emergency Use Authorization in November 2020 for certain high-risk, non-hospitalized COVID-19 patients.
Financial performance and key metrics
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Revenue | $8,497.1 million | $6,557.6 million | +29.6% |
| Net income | $3,513.2 million | $2,115.8 million | +66.0% |
| Diluted EPS | $30.52 | $18.46 | +65.3% |
| Income from operations | $3,576.6 million | $2,209.8 million | +61.8% |
| Operating margin | 42.1% | 33.7% | +8.4 percentage points |
| Net margin | 41.4% | 32.3% | +9.1 percentage points |
| Cash flow from operations | $2,618.1 million | $2,430.0 million | +7.7% |
Fourth-quarter 2020 revenue was $2,422.9 million, compared with $1,863.5 million in the fourth quarter of 2019. Fourth-quarter net income was $1,149.2 million, or $10.24 diluted EPS, compared with $792.0 million, or $6.93 diluted EPS, in the prior-year quarter.
- Net product sales were $5,567.6 million, including U.S. EYLEA sales of $4,947.2 million, Dupixent sales recorded by Regeneron and collaborators of $4,044.8 million, and REGEN-COV U.S. sales of $185.7 million.
- Sanofi collaboration revenue increased to $1,186.4 million from $403.6 million, primarily reflecting higher Dupixent-related profits, a $50.0 million sales milestone, and manufacturing reimbursements.
- Bayer collaboration revenue was $1,186.1 million, including $1,107.9 million of Regeneron’s net profit from EYLEA commercialization outside the United States.
- Research and development expense increased 11.6% to $2,735.0 million, including $290.7 million of direct REGEN-COV costs and $85.0 million of Intellia-related upfront payments.
- Cost of goods sold increased to $491.9 million, partly due to REGEN-COV and Praluent U.S. product sales and higher EYLEA and Libtayo sales. Inventory write-downs and reserves were $39.2 million.
- The effective tax rate declined to 7.8% from 12.9%, primarily due to stock-based compensation, research tax credits, and lower-tax foreign income.
Liquidity, cash flow, debt, and capital allocation
- Cash, cash equivalents, and marketable securities totaled $6,722.6 million at year-end, compared with $6,471.1 million in 2019. Cash and cash equivalents were $2,193.7 million.
- Working capital was $7,081.7 million, up from $5,592.5 million.
- Operating cash flow was $2,618.1 million. Investing cash flow was negative $70.6 million, including $614.6 million of capital expenditures. Financing cash flow was negative $1,970.5 million, primarily reflecting share repurchases and employee tax-withholding payments.
- The company issued $1,250.0 million of 1.750% senior notes due 2030 and $750.0 million of 2.800% senior notes due 2050. Long-term debt was $1,978.5 million, and finance lease liabilities were $717.2 million.
- No borrowings were outstanding under the $750.0 million revolving credit facility, and the company was in compliance with applicable covenants.
- Capital expenditures are expected to be $600 million to $680 million in 2021, principally for manufacturing, fill/finish, and research-facility expansion.
- The company completed a $5.0 billion purchase of Regeneron shares from Sanofi in May 2020 and completed the previously authorized $1.0 billion share-repurchase program. A new $1.5 billion repurchase authorization was approved in January 2021.
Material changes versus the prior comparable period
- Revenue growth was driven by stronger EYLEA, Dupixent, Libtayo, and collaboration economics, as well as initial REGEN-COV sales.
- Effective April 1, 2020, Regeneron assumed sole responsibility for Praluent development and commercialization in the United States, while Sanofi assumed responsibility outside the United States and pays Regeneron a 5% royalty on ex-U.S. sales through March 2032.
- Regeneron entered into a Roche collaboration for REGEN-COV and expanded its Intellia collaboration, making $70.0 million of upfront payments and purchasing $30.0 million of Intellia shares.
- Revenue and expense presentation for certain collaborator reimbursements and upfront or milestone payments was changed retrospectively, including reclassifications of prior-year amounts.
- Accounts receivable increased by $1,356.1 million and inventories increased by $529.4 million, partly due to extended EYLEA payment terms and supply-chain preparations related to COVID-19.
- Operating results benefited from a $99.8 million net cumulative catch-up adjustment in other operating income and a $95.0 million reversal of litigation-related accruals in the fourth quarter.
Guidance, outlook, management commentary, risks, and unusual items
- Management expects existing capital resources, operating cash flow, anticipated product sales, collaboration funding, and available credit to support anticipated operating needs for the foreseeable future, but continued profitability depends significantly on EYLEA and Dupixent.
- Management expects substantial continued spending on research and development, commercialization, manufacturing expansion, and REGEN-COV development and production during 2021.
- The U.S. government agreed to purchase up to $2.625 billion of additional REGEN-COV supply, subject to manufacturing capacity, authorized dose levels, and delivery conditions. A prior agreement could provide up to $465.9 million for manufacturing and related activities.
- COVID-19 affected EYLEA demand, clinical-trial execution, supply chains, commercial operations, and regulatory timelines. The ultimate impact remains uncertain.
- REGEN-COV remains subject to ongoing clinical trials, potential changes or revocation of its EUA, competition from vaccines and other treatments, manufacturing constraints, and reliance on third-party fill/finish providers.
- Key pipeline developments included discontinuation of active fasinumab treatment following an independent monitoring committee recommendation, a partial FDA clinical hold and enrollment pause for odronextamab, and a dosing pause for garetosmab after reports of fatal serious adverse events.
- Major risks include dependence on EYLEA and Dupixent, competition and potential biosimilars, reimbursement and drug-pricing reforms, manufacturing and supply-chain constraints, regulatory uncertainty, collaborator dependence, intellectual-property litigation, healthcare-law investigations, data-privacy risks, and stock-price volatility.
- Pending or disclosed legal matters include disputes concerning Praluent, Dupixent, EYLEA and its pre-filled syringe, REGEN-COV, fasinumab, a Department of Justice civil complaint and investigation, and claims by UnitedHealthcare. The filing does not provide a clear aggregate maximum potential loss for these matters.
Most important facts for investors to verify
- Confirm the sustainability of EYLEA and Dupixent growth and the extent of revenue concentration in these products and collaborators.
- Track U.S. EYLEA reimbursement and pricing developments, including the status and potential consequences of the Medicare Most Favored Nation rule.
- Verify REGEN-COV authorization, clinical data, government orders, manufacturing capacity, Roche execution, and inventory exposure.
- Review the $1.9785 billion of senior debt, $717.2 million of finance lease liabilities, and the approximately $3.103 billion contingent Sanofi development-cost reimbursement obligation.
- Assess the impact of EYLEA biosimilar competition and the stated U.S. regulatory exclusivity expiration date of November 18, 2023, subject to possible pediatric exclusivity.
- Monitor patent and government proceedings, particularly the EYLEA pre-filled syringe ITC case, Praluent litigation, and the Department of Justice matters.
- Reconcile reported revenue and expense trends for the retrospective collaborator-presentation changes and unusual fourth-quarter catch-up adjustments.
- Evaluate the company’s ability to fund expected 2021 capital expenditures of $600 million to $680 million while maintaining pipeline investment and share repurchases.